Sorafenib

• Description:

  Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

• Product Name Alternative:

  Bay 43-9006

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Sorafenib.html

• Purity:

  99.91

• Solubility:

  DMSO : ≥ 45 mg/mL

• Smiles:

  O=C(NC(C=C1)=CC=C1OC2=CC(C(NC)=O)=NC=C2)NC3=CC=C(Cl)C(C(F)(F)F)=C3

• Molecular Formula:

  C21H16ClF3N4O3

• Molecular Weight:

  464.83

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64 (19) :7099-109.|[2]El-Ashmawy NE, et al. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med. 2016 Apr 16.|[3]Jin W, et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Oncol Rep. 2017 Jan;37 (1) :273-280.|[4]Li M, et al. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. Br J Cancer. 2017 Aug 29.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  B-Raf; C-Raf; PDGFRβ; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4

• Citation 01:

  ACS Appl Mater Interfaces. 2017 Apr 12;9 (14) :12195-12202.|ACS Chem Biol. 2016 Apr 15;11 (4) :992-1000.|ACS Chem Biol. 2017 Jan 20;12 (1) :282-290. |ACS Nano. 2023 Nov 28;17 (22) :22240-22258.|ACS Omega. 2025 Oct 29;10 (44) :52562–52575.|Acta Pharm Sin B. 2023 Jun;13 (6) :2645-2662.|Acta Pharm Sin B. 2023 Oct;13 (10) :4253-4272.|Acta Pharm Sin B. 2025 Sep 17.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Adv Healthc Mater. 2023 Jul;12 (19) :e2203120.|Adv Sci (Weinh) . 2021 Jan 29;8 (6) :2002831.|Adv Sci (Weinh) . 2022 May;9 (15) :e2105894.|Adv Sci (Weinh) . 2023 Aug;10 (22) :e2206798.|Adv Sci (Weinh) . 2023 Sep;10 (27) :e2302640.|Adv Sci (Weinh) . 2024 Jul 9:e2402327.|Adv Sci (Weinh) . 2025 Aug 18:e08613.|Adv Sci (Weinh) . 2025 Jul 13:e02501.|Adv Sci (Weinh) . 2025 May 8:e2501730.|Advances in Parkinsons Disease. 2021, 10, 1-13.|Am J Dig Dis (Madison) . 2015;2 (2) :95-99.|Am J Hypertens. 2025 Jan 16;38 (2) :104-110.|Am J Transl Res. 2020;12 (3) :825-836.|Am J Transl Res. 2023 Feb 15;15 (2) :896-913.|Biochem Bioph Res Co. 2020 Sep 3;529 (4) :1086-1093.|Biochem Biophys Res Commun. 2022 Feb 19:593:122-128.|Biochem Biophys Res Commun. 2023 Sep 3:671:335-342.|Biochem Pharmacol. 2019 Nov:169:113612.|Biochem Pharmacol. 2023 Jul:213:115593.|Biochem Pharmacol. 2023 Jun:212:115554.|Biochim Biophys Acta Mol Cell Res. 2025 May 11:119989.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biol Direct. 2024 Nov 11;19 (1) :110.|Biol Direct. 2025 Apr 16;20 (1) :54.|Biology (Basel) . 2023 Oct 16;12 (10) :1337.|Biomater Adv. 2022 May:136:212761.|Biomaterials. 2022 Oct:289:121800.|Biomed Pharmacother. 2017 Feb:86:27-31.|Biomed Pharmacother. 2020 Jun;126:109862.|Biomed Pharmacother. 2022 Sep:153:113540.|Biomed Pharmacother. 2025 May 8:187:118136.|Biomed Res Int. 2019 Nov 28;2019:2410845.|Bioorg Chem. 2025 Aug 21:164:108903.|bioRxiv. 2021 Jan 25.|bioRxiv. 2025 Jul 12:2025.07.08.663754.|bioRxiv. 2025 Oct 15.|BMC Cancer. 2019 Aug 1;19 (1) :760.|BMC Complement Med Ther. 2023 Jun 26;23 (1) :210.|Br J Cancer. 2017 Sep 26;117 (7) :974-983.|Br J Pharmacol. 2021 Feb;178 (3) :636-653.|Braz J Med Biol Res. 2021 May 31;54 (9) :e10390.|Can J Gastroenterol Hepatol. 2022 Dec 24:2022:1206134.|Cancer Cell Int. 2019 Aug 27;19:222.|Cancer Cell Int. 2025 Oct 15;25 (1) :1-14.|Cancer Discov. 2019 Dec;9 (12) :1686-1695.|Cancer Discov. 2021 Oct;11 (10) :2544-2563.|Cancer Lett. 2019 May 28:450:132-143.|Cancer Lett. 2021 Nov 1:520:243-254.|Cancer Lett. 2022 Jan 1:524:161-171.|Cancer Res. 2025 Aug 21.|Cancers (Basel) . 2023 Nov 3;15 (21) :5280.|Cancers. 2020 Jun 30;12 (7) :1737.|Cell Biol Toxicol. 2023 Dec;39 (6) :2821-2839.|Cell Biol Toxicol. 2024 Nov 26;40 (1) :104.|Cell Commun Signal. 2024 Aug 7;22 (1) :391.|Cell Death Differ. 2021 Apr;28 (4) :1222-1236.|Cell Death Dis. 2021 Jul 9;12 (7) :691.|Cell Death Dis. 2022 Feb 4;13 (2) :118.|Cell Death Dis. 2023 Jan 12;14 (1) :22.|Cell Death Dis. 2024 Jan 18;15 (1) :66.|Cell Death Dis. 2024 Jun 5;15 (6) :395.|Cell Death Dis. 2025 Apr 6;16 (1) :257.|Cell Death Dis. 2025 Aug 28;16 (1) :654.|Cell Death Dis. 2025 Jan 26;16 (1) :42.|Cell Death Dis. 2025 Jul 11;16 (1) :512.|Cell Death Dis. 2025 Nov 17;16 (1) :839.|Cell Death Dis. 2019 Apr 15;10 (5) :331.|Cell Death Discov. 2022 Aug 17;8 (1) :365.|Cell Death Discov. 2023 Sep 30;9 (1) :362.|Cell Discov. 2022 May 3;8 (1) :40.|Cell Metab. 2021 Oct 5;33 (10) :2021-2039.e8.|Cell Mol Gastroenterol Hepatol. 2024 Dec 30:101454.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2023 Dec 12;42 (12) :113563.|Cell Rep. 2024 Nov 27;43 (12) :114996.|Cell Rep. 2024 Oct 24;43 (11) :114885.|Cell Signal. 2024 Jun 27:111278.|Cell Signal. 2025 Jun 6:111928.|Cell Signal. 2025 Sep:133:111872.|Chem Cent J. 2017 Jan 3:11:1.|Chemical Engineering and Applied Chemistry Institute of Biomaterials and Biomedical Engineering, University of Toronto. 2019 Aug.|Chemosphere. 2022 Dec;308 (Pt 2) :136354.|Chin J Nat Med. 2022 Mar;20 (3) :202-209.|Chin Med. 2024 Aug 24;19 (1) :113.|Clin Cancer Res. 2024 Sep 13;30 (18) :4179-4189.|Clin Epigenetics. 2025 Jul 7;17 (1) :120.|Clin Med Insights Oncol. 2024 Oct 16:18:11795549241285387.|Clin Sci. 2021 Jul 30;135 (14) :1751-1765.|Clin Sci. 2024 Sep 18;138 (18) :1131-1150.|Clin Transl Med. 2023 Jun;13 (6) :e1300.|Clin Transl Med. 2025 May;15 (5) :e70324.|Commun Biol. 2024 Oct 8;7 (1) :1279.|Commun Biol. 2025 Feb 8;8 (1) :205.|Comput Biol Med. 2024 Feb:169:107975.|Curr Issues Mol Biol. 2025 Apr 29;47 (5) :319.|Dig Liver Dis. 2024 Jan;56 (1) :176-186.|Discov Oncol. 2023 May 27;14 (1) :83.|Diseases. 2023 Oct 23;11 (4) :147.|Drug Deliv. 2023 Dec;30 (1) :2174209.|Drug Des Devel Ther. 2024 Sep 12:18:4065-4088.|Endocr J. 2017 Nov 29;64 (11) :1115-1123.|Endocrinology. 2023 Aug 28;164 (10) :bqad135.|Environ Toxicol. 2022 Feb;37 (2) :192-200.|Eur J Med Chem. 2024 Mar 5:267:116209.|Eur J Med Res. 2025 Aug 4;30 (1) :704.|Eur J Pharmacol. 2021 Sep 5:906:174217.|Eur J Pharmacol. 2025 Oct 21:1007:178274.|Evid Based Complement Alternat Med. 2022 Oct 15:2022:1911311.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Exp Cell Res. 2021 Sep 1;406 (1) :112755.|Exp Cell Res. 2022 Aug 15;417 (2) :113223.|Exp Hematol Oncol. 2016 Jul 29:5:22.|FASEB J. 2025 Aug 15;39 (15) :e70845.|Free Radic Biol Med. 2020 Nov 20;160:303-318.|Free Radic Biol Med. 2021 Feb 1;163:141-152.|Front Biosci (Landmark Ed) . 2024 Jan 19;29 (1) :35.|Front Oncol. 2021 Jul 13:11:704042.|Front Oncol. 2022 Jul 8;12:939605.|Front Pharmacol. 2022 Jul 11;13:930958.|Front Pharmacol. 2024 Apr 5.|Genes Dis. 2023 Sep 16;11 (4) :101114.|Gut Microbes. 2024 Jan-Dec;16 (1) :2410474.|Heliyon. 2024 Jan 13;10 (2) :e24461.|Heliyon. 2024 May 31;10 (11) :e32288.|Hepatol Commun. 2024 Mar 29;8 (4) :e0405.|Int Immunopharmacol. 2024 Sep 30;143 (Pt 1) :113226.|Int J Biol Macromol. 2025 Oct 9;330 (Pt 3) :148223.|Int J Biol Sci. 2018 Apr 25;14 (5) :577-585.|Int J Clin Exp Pathol. 2015 Apr 1;8 (4) :3871-81.|Int J Clin Exp Pathol. 2017;10 (3) :3033-3042.|Int J Environ Health Res. 2025 Apr 24:1-9.|Int J Med Sci. 2021 Jan 29;18 (6) :1456-1464.|Int J Mol Sci. 2023 Dec 23;25 (1) :269.|Int J Mol Sci. 2025 Sep 20;26 (18) :9185.|Int J Nanomedicine. 2024 Dec 3:19:12975-12998.|Integr Biol (Camb) . 2018 Oct 15;10 (10) :646-657.|iScience. 2023 May 29;26 (7) :106994.|J Biotechnol. 2025 Nov 12:410:1-9.|J Cancer. 2021 Jan 1;12 (2) :343-357.|J Cancer. 2025 Sep 8;16 (13) :3960-3971.|J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1:1061-1062:220-224.|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 15:1237:124100.|J Clin Transl Hepatol. 2025 Jan 28;13 (1) :15-24.|J Ethnopharmacol. 2021 Nov 15:280:114480.|J Exp Clin Cancer Res. 2022 Mar 30;41 (1) :116.|J Exp Clin Cancer Res. 2023 Jan 6;42 (1) :6.|J Exp Clin Cancer Res. 2018 Nov 29;37 (1) :295.|J Extracell Vesicles. 2024 Jul;13 (7) :e12468.|J Hazard Mater. 2025 Oct 19:499:140193.|J Hepatocell Carcinoma. 2023 Apr 11:10:611-629.|J Immunother Cancer. 2022 Aug;10 (8) :e004006.|J Med Chem. 2019 Nov 14;62 (21) :9593-9599. |J Med Chem. 2025 Apr 10;68 (7) :7367-7389.|J Mol Med (Berl) . 2022 Apr;100 (4) :585-598.|J Pharmacol Exp Ther. 2017 Aug;362 (2) :219-229. |J Transl Med. 2022 Jun 6;20 (1) :255.|J Transl Med. 2023 Jan 9;21 (1) :9.|J Transl Med. 2024 Aug 28;22 (1) :792.|J Transl Med. 2025 Apr 11;23 (1) :435.|J Transl Med. 2025 Feb 28;23 (1) :244.|Journal of Pharmaceutical Research International. 33 (47B) : 274-279, 2021.|Kaohsiung J Med Sci. 2022 Feb;38 (2) :157-164.|Lab Chip. 2018 Nov 6;18 (22) :3379-3392.|Lab Chip. 2025 Jul 23;25 (15) :3694-3706.|Liver Res. 2025 Sep 22.|Med Oncol. 2022 Sep 29;39 (12) :221.|MedComm (2020) . 2025 Nov 23;6 (12) :e70488.|Mol Cancer Ther. 2020 May;19 (5) :1197-1209.|Mol Carcinog. 2023 Sep;62 (9) :1295-1311.|Mol Carcinog. 2025 Jul;64 (7) :1264-1274.|Mol Cell Probes. 2023 Feb:67:101877.|Mol Cell. 2023 Dec 7;83 (23) :4334-4351.e7.|Mol Oncol. 2022 Oct;16 (20) :3703-3719.|Molecules. 2018 Mar 23;23 (4) . pii: E736.|Nat Cancer. 2024 Jul;5 (7) :1082-1101.|Nat Commun. 2022 Mar 18;13 (1) :1478.|Nat Commun. 2024 Sep 10;15 (1) :7923.|Nat Commun. 2025 Jan 2;16 (1) :87.|Nat Commun. 2025 Nov 18;16 (1) :10096.|Neuropharmacology. 2019 Apr:148:347-357.|Oncogene. 2021 Aug;40 (34) :5302-5313.|Oncogene. 2022 Mar;41 (13) :1851-1865.|Oncol Rep. 2017 Jan;37 (1) :273-280. |Oncol Rep. 2018 Sep;40 (3) :1525-1532. |Oncol Rep. 2021 Feb;45 (2) :776-785.|Oncol Res. 2025 May 29;33 (6) :1459-1472.|Oncotarget. 2017 May 2;8 (18) :29771-29784.|Pak J Zool. 2021 May.|Patent. US20180263995A1.|Patent. US20220305013A1.|Personalized Medicine Universe. 2019 May. |Pharmacol Res. 2022 Jun;180:106244.|Pharmacol Res. 2022 Mar:177:106050.|Phytochemistry. 2021 Sep:189:112816.|Phytomedicine. 2021 Nov:92:153740.|Phytomedicine. 2024 Jul:129:155225.|Phytomedicine. 2025 Apr 1:141:156692.|Phytomedicine. 2025 May 10:143:156840.|Phytomedicine. 2025 Oct 20:148:157423.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Prostate. 2018 Apr;78 (5) :343-352.|Redox Biol. 2023 Feb:59:102564.|Redox Biol. 2024 Jun:72:103131.|Redox Biol. 2024 Nov 5:78:103419.|Redox Biol. 2025 Sep:85:103786.|Res Sq. 2024 Sep 16.|Res Sq. 2025 Jul 13.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2022 Jul.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 Mar 29.|Research Square Preprint. 2023 Nov 11.|Research Square Print. 2023 Feb 20.|Research Square Print. October 3rd, 2022.|RSC Adv. 2018 8:6425-6435.|RSC Adv. 2025 Apr 14;15 (15) :11675-11687.|Scand J Immunol. 2023 Jul;98 (1) :e13271.|Sci Rep. 2017 Sep 8;7 (1) :11006. |Sci Rep. 2022 Apr 21;12 (1) :6120.|Sci Rep. 2025 Aug 7;15 (1) :28871.|Sci Rep. 2025 May 14;15 (1) :16724.|Sci Rep. 2025 Oct 15;15 (1) :36061.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Sens Actuators B Chem. 2024 Nov 1.|Signal Transduct Target Ther. 2023 Sep 14;8 (1) :348.|SSRN. 2023 Apr 24.|SSRN. 2023 Jan 27.|SSRN. 2024 Oct 16.|Stem Cell Res Ther. 2023 Apr 1;14 (1) :58.|Theranostics. 2020 Aug 21;10 (23) :10498-10512. |Toxicol In Vitro. 2021 Oct:76:105226.|Toxicol Mech Methods. 2025 Sep 10:1-8.|Toxicology. 2023 Apr:488:153475.|Toxicology. 2025 Jun 13:517:154220.|Transl Oncol. 2024 Nov 27:51:102214.|Virol Sin. 2023 Oct;38 (5) :778-786.|World J Gastroenterol. 2021 Jul 28;27 (28) :4667-4686.|Adv Sci (Weinh) . 2023 Jan;10 (3) :e2203718.|Am J Cancer Res. 2017 Dec 1;7 (12) :2503-2514. |Am J Transl Res. 2021 Jul 15;13 (7) :7508-7523.|Autophagy. 2022 Jan;18 (1) :191-203.|Bone Res. 2024 Apr 10;12 (1) :24.|Fundam Clin Pharmacol. 2021 Aug;35 (4) :690-699.|Int J Biochem Cell Biol. 2020 Sep;126:105820.|Int J Mol Sci. 2022 Sep 21;23 (19) :11092.|J Enzyme Inhib Med Chem. 2020 Dec;35 (1) :344-353.|Math Biosci Eng. 2019 Jul 8;16 (6) :6319-6334.|NAR Cancer. 2025 Aug 30;7 (3) :zcaf028.|NPJ Syst Biol Appl. 2019 Aug 16:5:29.|Oncotarget. 2017 Oct 6;8 (52) :90185-90196. |PLoS Genet. 2025 Mar 17;21 (3) :e1011614.|PLoS Negl Trop Dis. 2019 Aug 20;13 (8) :e0007681. |Saudi Pharm J. 2023 Jul;31 (7) :1317-1326.|Signal Transduct Target Ther. 2025 Aug 1;10 (1) :244.

• CAS Number:

  [284461-73-0]